

Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type 2 diabetes

13 June 2019

The results of a phase IIa clinical trial presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate a rapid reduction in albuminuria and hyperuricaemia in patients with type II diabetes with combined treatment of verinurad and febuxostat.

The primary endpoint of the study was met; results reveal a 39% reduction in [urinary albumin](#)-to-creatinine ratio (UACR) after 12 weeks with combined [treatment](#) of verinurad 9mg and febuxostat 80mg versus placebo ($p=0.07$). The study also shows a 57% reduction in [serum](#) urate (sUA) in the treatment group versus a 7% increase in the [placebo group](#) (p

APA citation: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type 2 diabetes (2019, June 13) retrieved 19 November 2019 from <https://medicalxpress.com/news/2019-06-verinurad-febuxostat-significantly-albuminuria-hyperuricaemia.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.